The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Jorgensen JT: Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development. Expert Rev. Mol. Diagn.8(6),689–695 (2008).
  MedlineGoogle Scholar
• 2  Jorgensen JT: New era of personalized medicine: a 10-year anniversary. Oncologist14(5),557–558 (2009).
  MedlineGoogle Scholar
• 3  Hu SX, Foster T, Kieffaber A: Pharmacogenomics and personalized medicine: mapping of future value creation. Biotechniques39(10 Suppl.),S1–S6 (2005).
  MedlineGoogle Scholar
• 4  Langreth R, Waldholz M: New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist4(5),426–427 (1999).
  Medline CASGoogle Scholar
• 5  Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov.6(4),287–293 (2007).
  Medline CASGoogle Scholar
• 6  Guyatt GH, Haynes RB, Jaeschke RZ et al.: Users’ guides to the medical literature: XXV. Evidence-based medicine: principles for applying the users’ guides to patient care. Evidence-Based Medicine Working Group. JAMA284(10),1290–1296 (2000).
  Medline CASGoogle Scholar
• 7  Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn’t. BMJ312(7023),71–72 (1996).
  Medline CASGoogle Scholar
• 8  Lauer MS, Collins FS: Using science to improve the nation’s health system: NIH’s commitment to comparative effectiveness research. JAMA303(21),2182–2183 (2010).
  Medline CASGoogle Scholar
• 9  Collins FS: Research agenda. Opportunities for research and NIH. Science327(5961),36–37 (2010).
  Medline CASGoogle Scholar
• 10  Ginsburg GS, Willard HF: Genomic and personalized medicine: foundations and applications. Transl. Res.154(6),277–287 (2009).
  MedlineGoogle Scholar
• 11  Kraushaar LE, Kramer A: Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention. BMC Public Health9,64 (2009).
  MedlineGoogle Scholar
• 12  Rich EC: The policy debate over public investment in comparative effectiveness research. J. Gen. Intern. Med.24(6),752–757 (2009).
  MedlineGoogle Scholar
• 13  Snyderman R, Yoediono Z: Perspective: prospective health care and the role of academic medicine: lead, follow, or get out of the way. Acad. Med.83(8),707–714 (2008).
  MedlineGoogle Scholar
• 14  Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat. Med.10(8),789–799 (2004).
  Medline CASGoogle Scholar
• 15  Van Cutsem E, Kohne CH, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14),1408–1417 (2009).
  Medline CASGoogle Scholar
• 16  Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT: Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther.86(1),109–113 (2009).
  Medline CASGoogle Scholar
• 17  Topol EJ: Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress? Sci. Transl. Med.2(44),44cm22 (2010).
  MedlineGoogle Scholar
• 18  Hamburg MA, Collins FS: The path to personalized medicine. N. Engl. J. Med.363(4),301–304 (2010).
  Medline CASGoogle Scholar
• 19  Tsapas A, Matthews DR: Using N-of-1 trials in evidence-based clinical practice. JAMA301(10),1022–1023; 1023 (2009).
  Medline CASGoogle Scholar
• 20  Guyatt GH, Jaeschke R: N-of-1 randomized trials – where do we stand? West. J. Med.152(1),67–68 (1990).
  Medline CASGoogle Scholar
• 21  Everitt BS, Pickler A: Statistical Aspects of The Design of Clinical Trials. Imperial College Press, London, UK (2004).
  Google Scholar
• 22  Gerss JW, Kopcke W: Clinical trials and rare diseases. Adv. Exp. Med. Biol.686,173–190 (2010).
  MedlineGoogle Scholar
• 23  Meinert CL, Tonascia S: Clinical Trials: Design, Conduct, and Analysis. Monographs in Epidemiology and Biostatistics. Oxford University Press, NY, USA, 469 (1986).
  Google Scholar
• 24  Barlow DH, Nock M, Hersen M: Single Case Experimental Designs: Strategies for Studying Behavior for Change (3rd Edition). Pearson/Allyn and Bacon, MA, USA, 393 (2009).
  Google Scholar
• 25  Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S: Determining optimal therapy – randomized trials in individual patients. N. Engl. J. Med.314(14),889–892 (1986).▪ Laid the foundation for n-of-1 trials in clinical medicine. Many other papers published by this research group further describe their years of experience in implementing n-of-1 trials.
  Medline CASGoogle Scholar
• 26  Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT: The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann. Intern. Med.112(4),293–299 (1990).
  Medline CASGoogle Scholar
• 27  Nikles J, Mitchell G, Walters J et al.: Prioritising drugs for single patient (n-of-1) trials in palliative care. Palliat. Med.23(7),623–634 (2009).
  Medline CASGoogle Scholar
• 28  Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS: What ever happened to n-of-1 trials? Insiders’ perspectives and a look to the future. Milbank Q.86(4),533–555 (2008).▪ Good review of the history of n-of-1 trials, including interviews with researchers who have been leaders in the field providing valuable direct insight into challenges of n-of-1 trials.
  MedlineGoogle Scholar
• 29  Kravitz RL, Paterniti DA, Hay MC et al.: Marketing therapeutic precision: potential facilitators and barriers to adoption of n-of-1 trials. Contemp. Clin. Trials30(5),436–445 (2009).
  MedlineGoogle Scholar
• 30  Kraemer HC, Frank E, Kupfer DJ: Moderators of treatment outcomes: clinical, research, and policy importance. JAMA296(10),1286–1289 (2006).
  Medline CASGoogle Scholar
• 31  Kraemer HC, Wilson GT, Fairburn CG, Agras WS: Mediators and moderators of treatment effects in randomized clinical trials. Arch. Gen. Psychiatry59(10),877–883 (2002).
  MedlineGoogle Scholar
• 32  Kent DM, Hayward RA: Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA298(10),1209–1212 (2007).
  Medline CASGoogle Scholar
• 33  Scuffham PA, Nikles J, Mitchell GK et al.: Using n-of-1 trials to improve patient management and save costs. J. Gen. Intern. Med.25(9),906–913 (2010).▪ Analysis using data from the clinical trial service developed in Australia of n-of-1 trials from the cost perspective.
  MedlineGoogle Scholar
• 34  Grande GE, Todd CJ: Why are trials in palliative care so difficult? Palliat. Med.14(1),69–74 (2000).
  Medline CASGoogle Scholar
• 35  Abrahm JL: A Physician’s Guide to Pain and Symptom Management in Cancer Patients (2nd Edition). Johns Hopkins University Press, MD, USA (2005).
  Google Scholar
• 36  Zucker DR, Schmid CH, McIntosh MW, D’Agostino RB, Selker HP, Lau J: Combining single patient (n-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J. Clin. Epidemiol.50(4),401–410 (1997).▪ This paper and a recently published follow-up paper discuss the statistical methodology involved in combining n-of-1 trials.
  Medline CASGoogle Scholar
• 37  Huber AM, Tomlinson GA, Koren G, Feldman BM: Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple n-of-1 clinical trials. J. Rheumatol.34(5),1125–1132 (2007).
  Medline CASGoogle Scholar
• 38  Senn S: Cross-over Trials in Clinical Research (2nd Edition). Wiley, Chichester, UK (2002).
  Google Scholar
• 39  Guyatt GH, Heyting A, Jaeschke R, Keller J, Adachi JD, Roberts RS: N-of-1 randomized trials for investigating new drugs. Control. Clin. Trials11(2),88–100 (1990).
  Medline CASGoogle Scholar
• 40  Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology46(1),135–140 (2007).
  Medline CASGoogle Scholar
• 41  Kazdin AE: Single-Case Research Designs: Methods for Clinical and Applied Settings. Oxford University Press, NY, USA, 368 (1982).
  Google Scholar
• 42  Barlow DH, Hersen M: Single Case Experimental Designs (2nd Edition). Allyn and Bacon, MA, USA (1984).
  Google Scholar
• 43  Spiegelhalter DJ: Statistical issues in studies of individual response. Scand. J. Gastroenterol. Suppl.147,40–45 (1988).
  Medline CASGoogle Scholar
• 44  Rochon J: A statistical model for the “n-of-1” study. J. Clin. Epidemiol.43(5),499–508 (1990).
  Medline CASGoogle Scholar
• 45  Topol EJ: Transforming medicine via digital innovation. Sci. Transl. Med.2(16),16cm4 (2010).▪ Recent paper that paints a picture of the future of medicine and the new age of digital medical devices that we are entering.
  MedlineGoogle Scholar
• 46  Plasqui G, Westerterp KR: Physical activity assessment with accelerometers: an evaluation against doubly labeled water. Obesity (Silver Spring)15(10),2371–2379 (2007).
  MedlineGoogle Scholar
• 47  Reid SC, Kauer SD, Dudgeon P, Sanci LA, Shrier LA, Patton GC: A mobile phone program to track young people’s experiences of mood, stress and coping. Development and testing of the mobiletype program. Soc. Psychiatry Psychiatr. Epidemiol.44(6),501–507 (2009).
  MedlineGoogle Scholar
• 48  Sudano I, Flammer AJ, Hermann F et al.: Auricall. A new device for a non-invasive, wireless, continuous monitoring of oxygen saturation and heart rate in patients with heart failure. Int. J. Cardiol.129(1),141–143 (2008).
  MedlineGoogle Scholar
• 49  Welch J, Guilak F, Baker S: A wireless ECG smart sensor for broad application in life threatening event detection. Conf. Proc. IEEE Eng. Med. Biol. Soc.5,3447–3449 (2004).
  MedlineGoogle Scholar
• 50  Wong LJ, Buckingham BA, Kunselman B, Istoc E, Leach J, Purvis R: Extended use of a new continuous glucose monitoring system with wireless data transmission in children with Type 1 diabetes mellitus. Diabetes Technol. Ther.8(2),139–145 (2006).
  MedlineGoogle Scholar
• 51  Vlassov VV, Laktionov PP, Rykova EY: Circulating nucleic acids as a potential source for cancer biomarkers. Curr. Mol. Med.10(2),142–165 (2010).
  Medline CASGoogle Scholar
• 52  Wu H, Chen H, Hu PC: Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. Clin. Lab.53(5–6),285–295 (2007).
  MedlineGoogle Scholar
• 53  Zucker DR, Ruthazer R, Schmid CH: Individual (n-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J. Clin. Epidemiol.63(12),1312–1323 (2010).
  MedlineGoogle Scholar
• 54  Larson EB, Ellsworth AJ, Oas J: Randomized clinical trials in single patients during a 2-year period. JAMA270(22),2708–2712 (1993).▪ Another research group’s experience of conducting n-of-1 trials is described here. They review the feasibility of n-of-1 trials from a patient, physician and cost perspective.
  Medline CASGoogle Scholar
• 55  Mahon J, Laupacis A, Donner A, Wood T: Randomised study of n-of-1 trials versus standard practice. BMJ312(7038),1069–1074 (1996).
  Medline CASGoogle Scholar
• 56  Nikles CJ, Mitchell GK, Del Mar CB, Clavarino A, McNairn N: An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder. Pediatrics117(6),2040–2046 (2006).▪ Published by a research group that implemented an n-of-1 service in Australia to treat attention deficit and hyperactivity disorder.
  MedlineGoogle Scholar
• 57  Pope JE, Prashker M, Anderson J: The efficacy and cost effectiveness of n-of-1 studies with diclofenac compared with standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. J. Rheumatol.31(1),140–149 (2004).
  MedlineGoogle Scholar
• 58  Scuffham PA, Yelland MJ, Nikles J, Pietrzak E, Wilkinson D: Are n-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience. Value Health11(1),97–109 (2008).
  MedlineGoogle Scholar
• 59  Chow SC, Chang M: Adaptive Design Methods in Clinical Trials. Chapman Hall, FL, USA (2007).
  Google Scholar
• 60  Rausch TL, Judd TM: The development of an interoperable roadmap for medical devices. Conf. Proc. IEEE Eng. Med. Biol. Soc. Suppl. 6740–6743 (2006).
  MedlineGoogle Scholar
• 61  Cepeda MS, Acevedo JC, Alvarez H, Miranda N, Cortes C, Carr DB: An n-of-1 trial as an aid to decision-making prior to implanting a permanent spinal cord stimulator. Pain Med.9(2),235–239 (2008).
  MedlineGoogle Scholar
• 62  Nathan PC, Tomlinson G, Dupuis LL et al.: A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial n-of-1 trials design. Support. Care Cancer14(3),268–276 (2006).
  Medline CASGoogle Scholar
• 63  Woodfield R, Goodyear-Smith F, Arroll B: N-of-1 trials of quinine efficacy in skeletal muscle cramps of the leg. Br. J. Gen. Pract.55(512),181–185 (2005).
  MedlineGoogle Scholar
• 64  Nikles CJ, Yelland M, Glasziou PP, Del Mar C: Do individualized medication effectiveness tests (n-of-1 trials) change clinical decisions about which drugs to use for osteoarthritis and chronic pain? Am. J. Ther.12(1),92–97 (2005).
  MedlineGoogle Scholar
• 65  Notcutt W, Price M, Miller R et al.: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘n-of-1’ studies. Anaesthesia59(5),440–452 (2004).
  MedlineGoogle Scholar
• 66  Haas DC, Sheehe PR: Dextroamphetamine pilot crossover trials and n-of-1 trials in patients with chronic tension-type and migraine headache. Headache44(10),1029–1037 (2004).
  MedlineGoogle Scholar
• 67  Wegman AC, van der Windt DA, de Haan M, Deville WL, Fo CT, de Vries TP: Switching from NSAIDs to paracetamol: a series of n-of-1 trials for individual patients with osteoarthritis. Ann. Rheum. Dis.62(12),1156–1161 (2003).
  Medline CASGoogle Scholar
• 68  Jansen IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH: Toward individualized evidence-based medicine: five ‘n-of-1’ trials of methylphenidate in geriatric patients. J. Am. Geriatr. Soc.49(4),474–476 (2001).
  Medline CASGoogle Scholar
• 69  Haines DR, Gaines SP: N-of-1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain83(2),283–287 (1999).
  Medline CASGoogle Scholar
• 70  March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P: N-of-1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ309(6961),1041–1045; discussion 1045–1046 (1994).
  Medline CASGoogle Scholar
• 71  Nonoyama ML, Brooks D, Guyatt GH, Goldstein RS: Ambulatory gas usage in patients with chronic obstructive pulmonary disease and exertional hypoxemia. J. Cardiopulm. Rehabil. Prev.28(5),323–329 (2008).
  MedlineGoogle Scholar
• 72  Hackett A, Gillard J, Wilcken B: N-of-1 trial for an ornithine transcarbamylase deficiency carrier. Mol. Genet. Metab.94(2),157–161 (2008).
  Medline CASGoogle Scholar
• 73  Martin RT, Whyte J: The effects of methylphenidate on command following and yes/no communication in persons with severe disorders of consciousness: a meta-analysis of n-of-1 studies. Am. J. Phys. Med. Rehabil.86(8),613–620 (2007).
  MedlineGoogle Scholar
• 74  Sung L, Tomlinson GA, Greenberg ML et al.: Serial controlled n-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur. J. Cancer43(8),1269–1275 (2007).
  Medline CASGoogle Scholar
• 75  Baicus C, Baicus A: Spirulina did not ameliorate idiopathic chronic fatigue in four N-of-1 randomized controlled trials. Phytother. Res.21(6),570–573 (2007).
  Medline CASGoogle Scholar
• 76  Pereira JA, Holbrook AM, Dolovich L et al.: Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann. Pharmacother.39(7–8),1188–1193 (2005).
  Medline CASGoogle Scholar
• 77  Coxeter PD, Schluter PJ, Eastwood HL, Nikles CJ, Glasziou PP: Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement. Ther. Med.11(4),215–222 (2003).
  Medline CASGoogle Scholar
• 78  Smith BJ, Appleton SL, Veale AJ, McElroy HJ, Veljkovic D, Saccoia L: Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol. Chron. Respir. Dis.1(2),63–69 (2004).
  Medline CASGoogle Scholar
• 79  Suri R, Metcalfe C, Wallis C, Bush A: Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatr. Pulmonol.37(4),305–310 (2004).
  MedlineGoogle Scholar
• 80  Price JD, Grimley Evans J: An n-of-1 randomized controlled trial (‘n-of-1 trial’) of donepezil in the treatment of non-progressive amnestic syndrome. Age Ageing31(4),307–309 (2002).
  MedlineGoogle Scholar
• 81  Wolfe B, Del Rio E, Weiss SL et al.: Validation of a single-patient drug trial methodology for personalized management of gastroesophageal reflux disease. J. Manag. Care Pharm.8(6),459–468 (2002).
  MedlineGoogle Scholar
• 82  Bollert FG, Paton JY, Marshall TG, Calvert J, Greening AP, Innes JA: Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group. Eur. Respir. J.13(1),107–113 (1999).
  Medline CASGoogle Scholar
• 83  Kent MA, Camfield CS, Camfield PR: Double-blind methylphenidate trials: practical, useful, and highly endorsed by families. Arch. Pediatr. Adolesc. Med.153(12),1292–1296 (1999).
  Medline CASGoogle Scholar
• 84  Mahon JL, Laupacis A, Hodder RV et al.: Theophylline for irreversible chronic airflow limitation: a randomized study comparing n-of-1 trials to standard practice. Chest115(1),38–48 (1999).
  Medline CASGoogle Scholar